Will GALEN become more RELEVANT? Editorial
| Authors: | von Keudell, G.; Younes, A. |
| Title: | Will GALEN become more RELEVANT? |
| Keywords: | cancer chemotherapy; treatment outcome; overall survival; lenalidomide; note; rituximab; clinical practice; cancer immunotherapy; progression free survival; quality of life; phosphatidylinositol 3 kinase; monoclonal antibody; medical literature; follicular lymphoma; marginal zone lymphoma; disease exacerbation; randomized controlled trial (topic); clinical trial (topic); phase 2 clinical trial (topic); ofatumumab; human; priority journal; copanlisib; obinutuzumab |
| Journal Title: | The Lancet Haematology |
| Volume: | 6 |
| Issue: | 8 |
| ISSN: | 2352-3026 |
| Publisher: | Elsevier Science, Inc. |
| Date Published: | 2019-08-01 |
| Start Page: | e391 |
| End Page: | e392 |
| Language: | English |
| DOI: | 10.1016/s2352-3026(19)30136-x |
| PUBMED: | 31296424 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Note -- Export Date: 4 September 2019 -- Source: Scopus |
